Cargando…

The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study

Background: The addition of pertuzumab to trastuzumab in neoadjuvant chemotherapy (NAC) for anti-human epidermal receptor 2 (HER2) positive breast cancer has shown a significant improvement in the pathologic complete response (pCR) rate. However, the add-on effect of an anthracycline-based regimen (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshino, Ryusei, Yoshida, Nana, Ujiie, Nanami, Nakatsubo, Masaki, Tanino, Mishie, Kitada, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694781/ http://dx.doi.org/10.7759/cureus.48255

Ejemplares similares

Surgical Treatment of Secondary Pneumothorax-Complicated Interstitial Lung Disease
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Radiation-Associated Breast Angiosarcoma
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Two Cases of Breast Cancer With Gastric Metastasis
por: Ito, Akane, et al.
Publicado: (2023)

Surgical resection of a large invasive mucinous adenocarcinoma: A case report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Concurrent Granulomatous Mastitis and Ductal Carcinoma In Situ
por: Yoshida, Nana, et al.
Publicado: (2023)

Subareolar Breast Abscess in a Male: A Case Report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Granulomatous Mastitis Occurring during Pregnancy: A Case Report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2021)

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial
por: Wu, Wei, et al.
Publicado: (2017)

Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alves, Fátima R, et al.
Publicado: (2022)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

A Case of Pneumothorax Ex Vacuo Associated with COVID-19
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Primary Dedifferentiated Liposarcoma of the Posterior Mediastinum With a Positive Surgical Margin
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Solitary fibrous tumor resembling pulmonary fractionation disease: A case report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Synchronous multiple lung cancers with hilar lymph node metastasis of small cell carcinoma: A case report
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
por: Mudgal, Shikha, et al.
Publicado: (2023)

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
por: Melcher, A. A., et al.
Publicado: (1996)

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation
por: Leong, T, et al.
Publicado: (2003)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

Clinical outcomes of neoadjuvant chemotherapy for patients with breast cancer: Tri-weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide: a retrospective observational study
por: Shizuku, Masato, et al.
Publicado: (2020)

Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Carcinoma: A Potential Area of Focus for Future Diagnostics
por: Kaur, Simrandeep, et al.
Publicado: (2022)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis
por: Magalhães, Denise, et al.
Publicado: (2023)

The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study
por: Russo, Francesco, et al.
Publicado: (2013)

Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
por: Zhang, Mengmeng, et al.
Publicado: (2020)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

Fluorouracil Catabolism in the Combination Treatment of Cyclophosphamide, Methotrexate and Fluorouracil
por: De Bruijn, Ernst A., et al.
Publicado: (1992)

Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings
por: Hashmi, Atif A, et al.
Publicado: (2023)

The Role of 5-Fluorouracil in Preventing Recurrence After Enucleation of Odontogenic Keratocyst: A Case Report
por: Barua, Chuimee Gogoi, et al.
Publicado: (2023)

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)
por: Riccardi, A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_mo2qrgl58dq0a58ll9fdknfhgp